July 24, 2024 04:15 PM Eastern Daylight Time IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term […]
Tag: JenaValve
egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference
ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc., a leading digital health company for cardiovascular care, and JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, unveil a novel study presented at the American College of Cardiology’s Annual […]
JenaValve’s Trilogy THV System Highlighted at CRT 2024
IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the Cardiovascular Research Technologies (CRT) Conference 2024. JenaValve’s Trilogy THV system, a TAVR system designed to treat patients with symptomatic, severe aortic regurgitation (ssAR), and symptomatic, severe aortic stenosis (ssAS), was featured in multiple scientific sessions highlighting the significant unmet need for devices to treat ssAR.
JenaValve Featured at the PCR London Valves 2023
IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from PCR London Valves 2023, a leading, annual global valve conference. The Trilogy THV system […]
JenaValve Announces Partnership with the American Society of Echocardiography (ASE) to Advance Detection and Diagnosis of Aortic Regurgitation
IRVINE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that it will join the American Society of Echocardiography (ASE) Industry Roundtable in 2024. Together, JenaValve […]
JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial Meeting Safety and Efficacy Endpoints
IRVINE, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced results from the ALIGN-AR Pivotal Trial for the Trilogy THV System in high-risk patients with symptomatic, […]
JenaValve Appoints Shlomi Nachman to Board of Directors
IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors. Mr. Nachman […]
JenaValve Announces First Trilogy Heart Valve Systems Implanted in Asia
IRVINE, Calif., May 18, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the completion of the first two Trilogy Heart Valve System implantations in Asia. The two procedures […]
JenaValve Appoints Ken MacLeod, Ph.D. to Board of Directors
IRVINE, Calif., April 05, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Ken MacLeod, Ph.D., life sciences and medical device industry veteran, to its […]
JenaValve Appoints Dan Dearen to Board of Directors
IRVINE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Dan Dearen, medical device industry executive, to its Board of Directors. Mr. […]
Recent
BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Popular
- No commented posts yet